Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
Howard I. Scher(Memorial Sloan Kettering Cancer Center), Ryan Dittamore(Epic Sciences (United States))
Cited by 635
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k